atorvastatin

AssetSmall moleculeAlso BR1017-2, Ezetimibe/Atorvastatin, Fimasartan, Atorvastatin, Lipilou

HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels

Stage: Approved
Modality: Small molecule
Target: AMPK signalling
Indications: 44
Trials: 732
Developers: 7

Indications

44

Angina
Approvedaccessdata.fda.gov7 Oct 2026
Coronary heart disease
Approvedaccessdata.fda.gov7 Oct 2026
Dysbetalipoproteinemia
Approvedaccessdata.fda.gov7 Oct 2026

41 more

Targets and what it contains5
Owner and partners7
Trials732
Evidence for its targets5
Competitors12
Aging relevance2
Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 53 sources